116 related articles for article (PubMed ID: 34520770)
1. TAD1822-7 induces ROS-mediated apoptosis of HER2 positive breast cancer by decreasing E-cadherin in an EphB4 dependent manner.
Zhu M; Tang X; Gong Z; Tang W; Zhang Y
Life Sci; 2021 Nov; 285():119954. PubMed ID: 34520770
[TBL] [Abstract][Full Text] [Related]
2. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
[TBL] [Abstract][Full Text] [Related]
3. Induction of estrogen receptor β-mediated autophagy sensitizes breast cancer cells to TAD1822-7, a novel biphenyl urea taspine derivative.
Su Q; Wu Q; Chen K; Wang J; Sarwar A; Zhang Y
Mol Biol Rep; 2022 Feb; 49(2):1223-1232. PubMed ID: 34792729
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.
Gupta P; Srivastava SK
BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293
[TBL] [Abstract][Full Text] [Related]
6. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1315-23. PubMed ID: 21461888
[TBL] [Abstract][Full Text] [Related]
7. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.
Brouxhon SM; Kyrkanides S; Teng X; O'Banion MK; Clarke R; Byers S; Ma L
Mol Carcinog; 2014 Nov; 53(11):893-906. PubMed ID: 23776059
[TBL] [Abstract][Full Text] [Related]
8. Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines.
Trošt N; Hevir N; Rižner TL; Debeljak N
Int J Mol Med; 2013 Mar; 31(3):717-25. PubMed ID: 23314808
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
[TBL] [Abstract][Full Text] [Related]
10. Disruption of endothelial adherens junction by invasive breast cancer cells is mediated by reactive oxygen species and is attenuated by AHCC.
Haidari M; Zhang W; Wakame K
Life Sci; 2013 Dec; 93(25-26):994-1003. PubMed ID: 24211779
[TBL] [Abstract][Full Text] [Related]
11. Ephrin‑B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis‑free survival in breast cancer.
Magic Z; Sandström J; Perez-Tenorio G
Int J Oncol; 2019 Dec; 55(6):1275-1286. PubMed ID: 31638179
[TBL] [Abstract][Full Text] [Related]
12. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
13. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
14. Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer.
Huang WC; Su HH; Fang LW; Wu SJ; Liou CJ
Cells; 2019 Mar; 8(3):. PubMed ID: 30841634
[TBL] [Abstract][Full Text] [Related]
15. Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway.
Wang XF; Witting PK; Salvatore BA; Neuzil J
Biochem Biophys Res Commun; 2005 Jan; 326(2):282-9. PubMed ID: 15582575
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial-dependent anticancer activity of δ-tocotrienol and its synthetic derivatives in HER-2/neu overexpressing breast adenocarcinoma cells.
Viola V; Ciffolilli S; Legnaioli S; Piroddi M; Betti M; Mazzini F; Pierpaoli E; Provinciali M; Galli F
Biofactors; 2013; 39(4):485-93. PubMed ID: 23361894
[TBL] [Abstract][Full Text] [Related]
17. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Way TD; Kao MC; Lin JK
J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
[TBL] [Abstract][Full Text] [Related]
18. Ensemble clustering of phosphoproteomic data identifies differences in protein interactions and cell-cell junction integrity of HER2-overexpressing cells.
Schaberg KE; Shirure VS; Worley EA; George SC; Naegle KM
Integr Biol (Camb); 2017 Jun; 9(6):539-547. PubMed ID: 28492659
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
20. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.
Wu Y; Ginther C; Kim J; Mosher N; Chung S; Slamon D; Vadgama JV
Mol Cancer Res; 2012 Dec; 10(12):1597-606. PubMed ID: 23071104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
